Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U7GK
|
||||
| Former ID |
DAP000865
|
||||
| Drug Name |
Thalidomide
|
||||
| Synonyms |
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; K 17; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); K-17; N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Immunosuppressive Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H10N2O4
|
||||
| InChI |
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
|
||||
| InChIKey |
UEJJHQNACJXSKW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 50-35-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10112, 111716, 398060, 398061, 482479, 596356, 5642997, 7847819, 7980770, 8150004, 8153340, 10321467, 10524356, 11120267, 11120755, 11121243, 11121763, 11122243, 11335226, 11360465, 11362910, 11364734, 11365472, 11367296, 11368034, 11369858, 11371011, 11371012, 11372649, 11372899, 11373635, 11374612, 11375458, 11376196, 11378022, 11428259, 11450681, 11461437, 11466220, 11467340, 11484629, 11485800, 11488523, 11491530, 11492901, 11532929, 12013404, 14798889, 17405778, 22391552
|
||||
| SuperDrug ATC ID |
L04AX02
|
||||
| SuperDrug CAS ID |
cas=000050351
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor | Target Info | Inhibitor | [536993] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| NF-kappa B signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| mTOR signaling pathway | |||||
| Apoptosis | |||||
| TGF-beta signaling pathway | |||||
| Osteoclast differentiation | |||||
| Antigen processing and presentation | |||||
| Toll-like receptor signaling pathway | |||||
| NOD-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| TNF signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Type I diabetes mellitus | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Influenza A | |||||
| HTLV-I infection | |||||
| Herpes simplex infection | |||||
| Proteoglycans in cancer | |||||
| Asthma | |||||
| Inflammatory bowel disease (IBD) | |||||
| Systemic lupus erythematosus | |||||
| Rheumatoid arthritis | |||||
| Allograft rejection | |||||
| Graft-versus-host disease | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Apoptosis signaling pathway | ||||
| Wnt signaling pathway | |||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| Canonical NF-kappaB pathway | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Signaling events mediated by HDAC Class I | |||||
| TNF receptor signaling pathway | |||||
| Ceramide signaling pathway | |||||
| amb2 Integrin signaling | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| IL23-mediated signaling events | |||||
| HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||||
| Caspase Cascade in Apoptosis | |||||
| Cellular roles of Anthrax toxin | |||||
| Downstream signaling in naï | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| TGF Beta Signaling Pathway | |||||
| Cytokines and Inflammatory Response | |||||
| MAPK Signaling Pathway | |||||
| EV release from cardiac cells and their functional effects | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Cardiac Hypertrophic Response | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Aryl Hydrocarbon Receptor | |||||
| Apoptosis | |||||
| Nanoparticle triggered regulated necrosis | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Adipogenesis | |||||
| Allograft Rejection | |||||
| TNF alpha Signaling Pathway | |||||
| TWEAK Signaling Pathway | |||||
| Extrinsic Pathway for Apoptosis | |||||
| Folate Metabolism | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| Ref 536775 | Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85. | ||||
| Ref 542350 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.